Sector Experts

Ram Selvaraju

Aegis Capital

Image: Ram Selvaraju

Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg." He is currently an analyst with Aegis Capital Corp.




Recent Interviews

Bring On the Orphans: Aegis Capital's Raghuram Selvaraju Lays Out a Winning Biotech Strategy (8/14/14) For former drug researcher Raghuram "Ram" Selvaraju, picking biotech stocks is both science and art. It's about understanding the competitive landscape and the mechanisms of drug action, and then making sure all the pieces fit together for a plausible investment case. In this interview with The Life Sciences Report, the managing director and head of healthcare equity research at Aegis Capital lays out his growth hypothesis for companiesŚseveral targeting orphan diseasesŚthat he believes will nurture portfolios.

Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases (4/22/14) To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst. In this, the last of his three interviews with The Life Sciences Report, Selvaraju highlights micro-, small- and mid-cap biotech names with therapies that may add years to patients' lives and liftoff to investor portfolios.

Ram Selvaraju: A Pair of Companies Ride the Sea Change in Cancer Therapeutics (2/4/14) A new generation of oncology treatments is moving through clinical trials toward the market. These proposed products are revolutionary in both their approaches to disease and their expected efficacy. Raghuram "Ram" Selvaraju, armed with his background as a drug developer, has followed dozens of highly innovative small- and mid-cap biotech companies, many of which he originally spotted as micro caps. In his second of three interviews with The Life Sciences Report, the head of equity healthcare research at Aegis Capital Corp. highlights two names with huge growth prospects.

Recent Quotes

"CGIX has sufficient capital to fund operations to break even status." (8/14/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"ARNI's onapristone could potentially be a suprabillion-dollar drug upon approval." (8/13/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"CUR has two very credible shots on goal." (8/13/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"INO has demonstrated that it is the preeminent DNA-based immunotherapy company." (8/11/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CUR delivered an in line Q2/14, ending the period with $30.2M in cash." (8/8/14) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"NBS's AMR-001 Phase 2 study could pave the way for a transformative licensing agreement." (8/8/14) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"The final patient has been treated in CUR's Phase 2 NSI-566 study." (8/4/14) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"INO's trial met its primary endpoint with robust statistical significance." (7/24/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

more comments

"CUR presented favorable safety and efficacy data on NSI-189." (6/25/14) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CGIX's existing cash balance should be sufficient to fund operations through to profitability." (6/23/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"INO initiated a Phase 1/2a trial to evaluate responses to INO-3112." (6/10/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

"INO's shares of common stock are trading after a reverse stock split." (6/9/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CGIX entered into a partnership with AstraZeneca CAMCAR." (6/9/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"At ASCO, NBS showed the 5-year survival rate on melapuldencel-T was 50%." (6/2/14) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We reiterate our Buy rating for CUR and raise our price target." (5/27/14) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"INO's roughly $117M should fund operations at least through 2017." (5/21/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CGIX's announced acquisition could lead to future growth." (5/15/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CUR's science is cutting edge, and of a very high quality." (4/22/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"If the data from the PRESERVE trial are positive, NEO may be able to enter partnership in the regenerative medicine space." (4/22/14) NeoStem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"ARNI's onapristone could legitimately be considered a pipeline in a single product." (4/22/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"Gross margins for CGIX's base business could double in 18ľ24 months." (3/27/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CPRX is one of the most attractively valued specialty pharmaceuticals companies." (3/19/14) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"In the wake of CGIX's prestigious board appointment, we reiterate our Buy rating." (2/18/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CGXI is a leader in the molecular diagnostics field with the ability to generate high-margin revenue." (2/10/14) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"In the past week, CPRX released clean human safety data on Firdapse." (1/8/14) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We are initiating coverage on DRIO with a Buy rating." (1/8/14) LabStyle Innovations Corp. - Ram Selvaraju, Aegis Capital Moreá>

"We are reiterating our Buy rating on NBS and raising our original 15-month price target." (1/2/14) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We think that CGXI is an attractive investment at this juncture primarily because it has a diversified revenue model." (12/5/13) Cancer Genetics Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"DRIO is developing a very interesting approach to diagnostics at the level of data capture." (12/5/13) LabStyle Innovations Corp. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"We have raised our 12-month price target for CPRX to $6/share; the profile for CPP-115 keeps getting better and better." (11/25/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR's glioblastoma trial is a potentially significant value driver." (11/25/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CUR is entering a critical period in its history; we reiterate our Buy." (11/25/13) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"By late 2014, NBS could be trading at a price normally associated with companies valued at $700M+." (11/11/13) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We are raising our expectations on pricing for CPRX's lead drug candidate, Firdapse." (10/21/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We are initiating coverage on CGIX with a Buy rating." (9/26/13) Cancer Genetics Inc. - Ram Selvaraju, Aegis Capital Moreá>

"INO's cervical cancer vaccine results could position Inovio at the forefront of the vaccine field." (9/11/13) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CPRX has raised sufficient capital to sustain operations through 2014." (9/6/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR's aldoxorubicin has already shown highly encouraging results in animal cancer models." (8/29/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CPRX's breakthrough therapy designation from the FDA is a significant positive development." (8/27/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"The impact of CYTR's aldoxorubicin for glioblastoma could be significant and might permit an accelerated path to market." (8/19/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CUR closed Q2/13 with $11.2M in cash and equivalents, which we anticipate to be sufficient to fund operations well into 2014." (8/16/13) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We maintain our Buy rating on CPRX and raise our 12 month price target." (8/16/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"NBS completed a reverse stock split; it will be listed on the NASDAQ." (7/25/13) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"Firdapse could generate $80ľ100M in sales every year for CPRX, which has a $40M market cap." (7/18/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"CYTR's lead compound, aldoxorubicin, is a risk-mitigated opportunity." (7/18/13) CytRx Corp. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"We continue to be positive on GALE's NeuVax, which is proposed to prevent recurrence of breast cancer in disease-free patients." (7/18/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"We continue to be very bullish on LPTN's prospects to deliver positive results in the ongoing NEXUS study." (7/18/13) Lpath Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"NBS' reverse stock split could pave the way for easier institutional ownership of the stock." (7/18/13) NeoStem Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"CUR is one of the best stories in the stem cell arena and it has a rich calendar of catalysts in 2013 and into H1/14." (7/18/13) Neuralstem Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>

"CYTR showed aldoxorubicin to regress brain tumor growth in animals." (7/11/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CPRX's Firdapse enrollment status is encouraging." (6/28/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We are initiating coverage of NBS with a Buy rating." (6/24/13) NeoStem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR is advancing aldoxorubicin and has reported positive test results." (6/19/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CUR will soon begin dosing of NSI-566 in a phase 2 trial; this is a significant step forward." (5/20/13) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR reached an agreement with the FDA for a Special Protocol Assessment on a global pivotal phase 3 trial with aldoxorubicin." (4/24/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"Approval to begin phase 2 testing in patients with ALS is a significant step forward for CUR." (4/17/13) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR is well capitalized to fund operations through the important catalysts expected over the next next 12ľ15 months." (3/28/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"Animal data has indicated LPTN's ASONEP™ may have activity in renal cell carcinoma, including that which is resistant to currently marketed drugs." (3/14/13) Lpath Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We reiterate our Buy rating on GALE." (3/13/13) Galena Biopharma Inc. - Ram Selvaraju, Aegis Capital Moreá>

"GALE is an intriguing investment opportunity at this juncture." (3/13/13) Galena Biopharma Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We consider LPTN's agreement with Provista a further validation of its ImmuneY2 platform." (3/7/13) Lpath Inc. - Ram Selvaraju, Aegis Capital Moreá>

"CYTR represents an undervalued entity in the oncology arena." (2/28/13) CytRx Corp. - Ram Selvaraju, Aegis Capital Moreá>

"CUR had a phenomenal year in 2012." (2/14/13) Neuralstem Inc. - The Life Sciences Report interview with Ram Selvaraju Moreá>

"It is very rare to see a $60M market cap company with all the positive attributes LPTN has." (2/14/13) Lpath Inc. - The Life Sciences Report interview with Ram Selvaraju Moreá>

"GALE is a promising story; it is attacking breast cancer with a vaccine." (2/14/13) Galena Biopharma Inc. - The Life Sciences Report interview with Ram Selvaraju Moreá>

"CUR has received FDA approval to move into spinal cord injury." (1/14/13) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We reiterate our Buy rating on LPTN." (1/4/13) Lpath Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We consider GALE an intriguing investment opportunity." (12/10/12) Galena Biopharma Inc. - Ram Selvaraju, Aegis Capital Moreá>

"In anticipation of two CUR catalysts, we reiterate our Buy rating." (12/10/12) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"GALE has linked up with an excellent partner in Teva Pharmaceuticals." (12/4/12) Galena Biopharma Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We consider GALE an intriguing investment opportunity." (11/28/12) Galena Biopharma Inc. - Ram Selvaraju, Aegis Capital Moreá>

"VPT's technology platform is very interesting and is fundamentally underrated and misunderstood by the market." (11/1/12) VentriPoint Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"LPTND has undertaken a capital-efficient approach to drug development." (11/1/12) Lpath Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"The science underlying CUR, in my opinion, is truly world class." (11/1/12) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>

"CUR has made progress on a range of fronts." (10/15/12) Neuralstem Inc. - Ram Selvaraju, Aegis Capital Moreá>

"We are reiterating our Buy rating on IGXT and raising our price target." (10/4/12) IntelGenx Corp. - Ram Selvaraju, Aegis Capital Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.